StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $7.33 | $7.68 | +4.77% | 1.0M |
| 05-12 | $7.67 | $7.72 | +0.65% | 1.0M |
| 05-13 | $7.50 | $7.38 | -1.60% | 1.6M |
| 05-14 | $7.50 | $7.63 | +1.73% | 1.5M |
| 05-15 | $7.43 | $6.92 | -6.86% | 2.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2022 2022-12-31 | Annual 2021 2021-12-31 | Annual 2020 2020-12-31 | Q3 2020 2020-09-30 |
|---|---|---|---|---|
Revenue | $8.09M | $13.62M | $0.00 | $0.00 |
Operating Income | $-106.45M | $-72.25M | $-88.41M | $-67.06M |
Net Income | $-85.98M | $-72.19M | $-88.29M | $-66.93M |
EPS (Diluted) | $-10.10 | $-10.14 | $-25.50 | Not available |
Total Assets | $260.25M | $232.38M | $171.17M | $40.52M |
Total Liabilities | $48.59M | $24.17M | $39.08M | $18.29M |
Cash & Equivalents | $155.38M | $119.14M | $154.74M | $24.80M |
Free Cash Flow OCF − CapEx | $-100.99M | $-79.05M | $-57.50M | $-58.74M |
Shares Outstanding | 19.56M | 7.36M | 84.89M | 46.18M |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
No sell-side coverage available for SLDB.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for SLDB.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.